Tuesday, December 10, 2013 9:59:19 PM
How sweet it is!
I've been seeing "David Carbone" through my list of research for "MONTHS!" and after looking at his background/history/affiliates many times before, I never would have never, ever have expected his name to fill a void on this Peregrines website. All of them are highly respected and I only mention David Carbone because for some reason, through all that research.... his name continued to pop up and he lands at Peregrine.
BAMM.... that bumpy road Dr. Garnick talked about many months ago has simply smoothed out a bit...
If you follow the chain of posts back... you'll see everyone was split between Medical/Scientic/Infectious-Antiviral/ Advisors and now we have one happy group all lumped under:
Dr. Philip E. Thorpe .... RIP and hopefully approves of the new and final? list
* = part of original team of advisors
** = replaced Dr. Philip E. Thorpe
*** = part of the new addition of 4 just added 12/10/2013
Medical and Scientific Advisors:
*** Scott J. Antonia, M.D., Ph.D.
Department Chair, Program Leader, Thoracic Oncology Department Associate Professor Department of Interdisciplinary Oncology and Program Leader of the Immunology Program
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
** Rolf Brekken, Ph.D.
Associate Professor, Hamon Center for Therapeutic Oncology Research
UT Southwestern Medical Center
*** David Carbone, M.D., Ph.D.
Professor of Medicine, Division of Medical Oncology
Ohio State University’s Ohio State’s Comprehensive Cancer Center at the James Cancer Hospital and Solove Research Institute, Columbus, Ohio
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93337001&txt2find=david|carbone
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93541590&txt2find=david|carbone
* Bruce Chabner, M.D.
Clinical director of Massachusetts General Hospital (MGH) Cancer Center
Chief of Hematology and Oncology at MGH and a Professor of Medicine at Harvard Medical School
* Harold F. Dvorak, M.D.
Chief of the Department of Pathology at Beth Israel Deaconess Medical Center
Mallinckrodt Professor of Pathology at Harvard Medical School
*** Dimitry I. Gabrilovich, M.D., Ph.D.
Christopher M. Davis Professor in Cancer Research, Program Leader, Translational Tumor Immunology
The Wistar Institute, Philadelphia, Pennsylvania
* Christopher C. W. Hughes, Ph.D.
Professor, Departments of Molecular Biology and Biochemistry, & Biomedical Engineering
University California Irvine
*** Håkan Mellstedt, M.D., Ph.D.
Professor of Oncologic Biotherapy, Karolinska Institute and Cancer Centre Karolinska
Karolinska University Hospital, Stockholm, Sweden
* Alan J. Schroit, Ph.D.
Professor of Cancer Biology
M.D. Anderson Cancer Center, Houston
http://www.peregrineinc.com/about-us/medical-and-scientific-advisors.html
--------------------------------------------------------------
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
Recent CDMO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:50:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:48:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 08:40:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 12:23:26 AM
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM
Kona Gold Beverage Significantly Reduces Debt from Multiple Holders • KGKG • Jul 31, 2024 9:00 AM
Avant Technologies Opens Equity Line with GHS Investments as Company Explores Expansion into Additional Technologies • AVAI • Jul 30, 2024 8:00 AM
ELEMENT79 GOLD CORP PROVIDES UPDATE ON CHACHAS COMMUNITY CHARTER AND REVENUE GENERATION, M&A ACTIVITIES • ELMGF • Jul 30, 2024 8:00 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM